Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

slate run pharmaceuticals - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine injection, usp is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risk of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine hydrochloride is contraindic

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

physicians total care, inc. - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine hydrochloride 12.5 mg in 1 ml - dobutamine injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. in patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to institution of therapy with dobutamine hydrochloride. dobutamine hydrochloride is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to dobutamine injection.

Канада - Енглески - Health Canada

hikma canada limited - dobutamine (dobutamine hydrochloride) - solution - 12.5mg - dobutamine (dobutamine hydrochloride) 12.5mg - selective beta 1-adrenergic agonists

Канада - Енглески - Health Canada

pfizer canada ulc - dobutamine (dobutamine hydrochloride) - solution - 250mg - dobutamine (dobutamine hydrochloride) 250mg - selective beta 1-adrenergic agonists

Канада - Енглески - Health Canada

sterimax inc - dobutamine (dobutamine hydrochloride) - solution - 12.5mg - dobutamine (dobutamine hydrochloride) 12.5mg - selective beta 1-adrenergic agonists

Сингапур - Енглески - HSA (Health Sciences Authority)

pfizer private limited - dobutamine hcl eqv dobutamine - injection - 12.5 mg/ml - dobutamine hcl eqv dobutamine 12.5 mg/ml

Малта - Енглески - Malta Medicines Authority

mercury pharmaceuticals (ireland) limited 4045 kingswood road, city west business park, co, dublin, ireland - dobutamine - concentrate for solution for infusion - dobutamine 12.5 mg/ml - cardiac therapy

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

claris lifesciences (uk) limited - dobutamine hydrochloride - concentrate for soln for inf - 12.5 mg/ml - adrenergic and dopaminergic agents

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

hameln pharma ltd - dobutamine hydrochloride - solution for infusion - 12.5mg/1ml

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine in 5% dextrose injection, usp is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risks of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine in 5% dextrose injection, usp is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to dobutamine or any of its components.